Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Colorcon
Mallinckrodt
Medtronic
Dow

Last Updated: August 17, 2022

TRELSTAR Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which patents cover Trelstar, and when can generic versions of Trelstar launch?

Trelstar is a drug marketed by Verity and is included in three NDAs. There is one patent protecting this drug.

This drug has forty-six patent family members in thirty-one countries.

The generic ingredient in TRELSTAR is triptorelin pamoate. There are three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the triptorelin pamoate profile page.

DrugPatentWatch® Generic Entry Outlook for Trelstar

Trelstar was eligible for patent challenges on June 15, 2004.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 30, 2029. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Summary for TRELSTAR
International Patents:46
US Patents:1
Applicants:1
NDAs:3
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 40
Clinical Trials: 10
Patent Applications: 3,116
Drug Prices: Drug price information for TRELSTAR
What excipients (inactive ingredients) are in TRELSTAR?TRELSTAR excipients list
DailyMed Link:TRELSTAR at DailyMed
Drug patent expirations by year for TRELSTAR
Drug Prices for TRELSTAR

See drug prices for TRELSTAR

DrugPatentWatch® Estimated Generic Entry Opportunity Date for TRELSTAR
Generic Entry Date for TRELSTAR*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
INJECTABLE;INTRAMUSCULAR

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for TRELSTAR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Bristol-Myers SquibbPhase 2
Sir Mortimer B. Davis - Jewish General HospitalPhase 2/Phase 3
Medical College of Wisconsin

See all TRELSTAR clinical trials

US Patents and Regulatory Information for TRELSTAR

TRELSTAR is protected by one US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of TRELSTAR is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting TRELSTAR

Slow release pharmaceutical composition made of microgranules
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Verity TRELSTAR triptorelin pamoate INJECTABLE;INTRAMUSCULAR 020715-001 Jun 15, 2000 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Verity TRELSTAR triptorelin pamoate INJECTABLE;INTRAMUSCULAR 021288-001 Jun 29, 2001 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Verity TRELSTAR triptorelin pamoate INJECTABLE;INTRAMUSCULAR 022437-001 Mar 10, 2010 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for TRELSTAR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Verity TRELSTAR triptorelin pamoate INJECTABLE;INTRAMUSCULAR 021288-001 Jun 29, 2001 See Plans and Pricing See Plans and Pricing
Verity TRELSTAR triptorelin pamoate INJECTABLE;INTRAMUSCULAR 020715-001 Jun 15, 2000 See Plans and Pricing See Plans and Pricing
Verity TRELSTAR triptorelin pamoate INJECTABLE;INTRAMUSCULAR 021288-001 Jun 29, 2001 See Plans and Pricing See Plans and Pricing
Verity TRELSTAR triptorelin pamoate INJECTABLE;INTRAMUSCULAR 020715-001 Jun 15, 2000 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for TRELSTAR

When does loss-of-exclusivity occur for TRELSTAR?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

African Regional IP Organization (ARIPO)

Patent: 00
Estimated Expiration: See Plans and Pricing

Australia

Patent: 08259411
Estimated Expiration: See Plans and Pricing

Brazil

Patent: 0812250
Estimated Expiration: See Plans and Pricing

Canada

Patent: 88478
Estimated Expiration: See Plans and Pricing

China

Patent: 1677959
Estimated Expiration: See Plans and Pricing

Colombia

Patent: 51234
Estimated Expiration: See Plans and Pricing

Croatia

Patent: 0161785
Estimated Expiration: See Plans and Pricing

Patent: 0181854
Estimated Expiration: See Plans and Pricing

Cyprus

Patent: 18434
Estimated Expiration: See Plans and Pricing

Patent: 20891
Estimated Expiration: See Plans and Pricing

Denmark

Patent: 64467
Estimated Expiration: See Plans and Pricing

Patent: 00014
Estimated Expiration: See Plans and Pricing

Eurasian Patent Organization

Patent: 9284
Estimated Expiration: See Plans and Pricing

Patent: 0971132
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 64467
Estimated Expiration: See Plans and Pricing

Patent: 00014
Estimated Expiration: See Plans and Pricing

Patent: 31077
Estimated Expiration: See Plans and Pricing

Hong Kong

Patent: 41737
Estimated Expiration: See Plans and Pricing

Hungary

Patent: 31550
Estimated Expiration: See Plans and Pricing

Patent: 40391
Estimated Expiration: See Plans and Pricing

Israel

Patent: 2501
Estimated Expiration: See Plans and Pricing

Japan

Patent: 19169
Estimated Expiration: See Plans and Pricing

Patent: 10529106
Estimated Expiration: See Plans and Pricing

Lithuania

Patent: 64467
Estimated Expiration: See Plans and Pricing

Patent: 00014
Estimated Expiration: See Plans and Pricing

Malaysia

Patent: 0450
Estimated Expiration: See Plans and Pricing

Mexico

Patent: 09012856
Estimated Expiration: See Plans and Pricing

Montenegro

Patent: 959
Estimated Expiration: See Plans and Pricing

Morocco

Patent: 422
Estimated Expiration: See Plans and Pricing

New Zealand

Patent: 2423
Estimated Expiration: See Plans and Pricing

Poland

Patent: 64467
Estimated Expiration: See Plans and Pricing

Patent: 00014
Estimated Expiration: See Plans and Pricing

Portugal

Patent: 64467
Estimated Expiration: See Plans and Pricing

Patent: 00014
Estimated Expiration: See Plans and Pricing

Serbia

Patent: 591
Estimated Expiration: See Plans and Pricing

Patent: 248
Estimated Expiration: See Plans and Pricing

Slovenia

Patent: 64467
Estimated Expiration: See Plans and Pricing

Patent: 00014
Estimated Expiration: See Plans and Pricing

South Africa

Patent: 0907940
Estimated Expiration: See Plans and Pricing

South Korea

Patent: 1631475
Estimated Expiration: See Plans and Pricing

Patent: 100023950
Estimated Expiration: See Plans and Pricing

Spain

Patent: 11020
Estimated Expiration: See Plans and Pricing

Patent: 94401
Estimated Expiration: See Plans and Pricing

Tunisia

Patent: 09000476
Estimated Expiration: See Plans and Pricing

Ukraine

Patent: 830
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TRELSTAR around the world.

Country Patent Number Title Estimated Expiration
European Patent Office 2164467 COMPOSITION PHARMACEUTIQUE À LIBÉRATION LENTE, FAITE DE MICROPARTICULES (SLOW RELEASE PHARMACEUTICAL COMPOSITION MADE OF MICROPARTICLES) See Plans and Pricing
Slovenia 2164467 See Plans and Pricing
Canada 2688478 COMPOSITION PHARMACEUTIQUE A LIBERATION LENTE, FAITE DE MICROPARTICULES (SLOW RELEASE PHARMACEUTICAL COMPOSITION MADE OF MICROPARTICLES) See Plans and Pricing
Canada 2021767 METHODE DE PREPARATION D'UN COMPOSE PHARMACEUTIQUE SOUS FORME DE MICROPARTICULES (METHOD FOR PREPARING A PHARMACEUTICAL COMPOSITION IN THE FORM OF MICROPARTICLES) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
Dow
Moodys
Medtronic
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.